SLS SELLAS Life Sciences Group, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
15:46
Sep 11
Sep 11
Whale exits signal rising SLS failure risk
The author argues that a remarkably large investor has fully exited their SLS position, with rumors that another prominent holder has also sold. This whale exodus is presented as evidence that the probability of the company's failure is now a major concern, a risk the author says is already reflected in the falling share price. The main stated risk is the underlying clinical/financial failure of the company itself.
MED
14:10
Sep 10
Sep 10
OrbiMed 13F shows huge SLS put bet
The author cites recent 13F filings from Perceptive Advisors and OrbiMed showing OrbiMed made a huge put bet against SLS, along with other biotech majors. The mechanism is that large institutional investors are positioned bearishly, implying they possess information or conviction that retail lacks. The author suggests that anyone committed to SLS should at least hedge, framing the institutions as knowing more than retail investors.
MED
11:23
Sep 09
Sep 09
SLS is binary; bad results crush the stock
The author characterizes Sellas (SLS) as a binary play whose share price would drop drastically if its clinical results are not that great. The mechanism is event-driven: the stock's value hinges on trial readout quality, so downside is severe on disappointing data. No specific timeline or numeric target is given, and the main risk is exactly the negative readout the author warns about.
HIGH
14:17
Sep 08
Sep 08
SLS Phase 3 data lock imminent
The author argues SELLAS is an event-driven opportunity as its Phase 3 REGAL trial for AML in second complete remission approaches data lock, needing only two more deaths to reach the 80-event threshold after 78 were reported on May 11. Interim analysis at 60 deaths showed overall survival of 12-13.5 months versus 6 months for standard treatment, and the trial succeeds if median OS is 12.6 months or higher. Top-line results typically follow data lock within 3 days to 5 weeks, with US TAM of ~9,000 patients and worldwide AML TAM of $3.2-4.2bn growing ~10% CAGR. Main risk is trial failure at the final analysis.
HIGH
15:02
Sep 06
Sep 06
Research list of high-risk speculative biotechs
The speaker recommends researching a list of speculative small-cap biotech names, acknowledging high risk, without endorsing a directional trade.
LOW
14:23
Sep 06
Sep 06
SLS watch, Phase 3 event
AI-generated Phase 3 binary bet; author holds no stake; watch.
MED
10:00
Aug 31
Aug 31
A +5 comment expects SLS loss porn after a dump to penny-stock territory overnight. Speculative expectation of a rapid collapse suggests panic-selling and downside momentum risk. Traders are positioned for a sharp SLS de-rating; avoid longs or consider short exposure. Only one explicit SLS comment; no fundamental data or counter-thesis in the thread. US TECH FUTURES (NQ) - SHORT | confidence: 0.50 | sentiment: -0.60 Speaker: r/wallstreetbets community Thesis: A commenter reports holding 29,400 puts on US Tech futures. Large derivative put holdings signal a serious bearish position on tech index futures. This is a notable short/put hedge against tech; respect the bearish macro tilt. NVDA bullish targets and AAPL strength in the thread contradict a tech breakdown.
LOW
00:32
Aug 31
Aug 31
Author is deploying borrowed money into SLS and plans to hold 3,500 shares by the catalyst event. The "80th event" is the expected trigger; heavy leverage amplifies any upside move. Event-driven leveraged long SLS; essentially a lottery-ticket YOLO bet. Margin call, loan default, binary biotech/clinical event failure, total account wipeout.
HIGH
16:08
Aug 26
Aug 26
Author compares street vs retail biotech top lists and notes RVMD approval with pricing.
Author compares street vs retail biotech top lists and notes RVMD approval with pricing expectations, but frames all names as observational research rather than personal positions.
LOW
10:00
Aug 24
Aug 24
“SLS baby. Let’s goooo” is met with “either cancer got cured... or this is dogshit fluff.” A biotech cancer/AI story with hype and skepticism likely creates a volatile two-way tape. Watch for a confirmed catalyst/volume breakout before acting; do not chase the story. “Age of spitting bullshit” warning; no fundamental data in thread; possible pump-and-dump.
LOW
20:00
Aug 23
Aug 23
SLS is currently trading around $15 and has historically run from $5 to $15.80 on previous momentum cycles. Imminent positive PR is expected to act as a catalyst, potentially triggering trading halts and pushing the stock into a much higher price discovery phase. Going long on SLS captures the upside of a highly volatile, catalyst-driven momentum play with significant historical price swings. It is a highly speculative penny/small-cap play, and if the PR fails to deliver, the stock could easily collapse back to its $5 base.
LOW
13:41
Aug 23
Aug 23
Author remains bullish on ABVX as largest position but trimmed equity for options, closed IVA.
Author remains bullish on ABVX as largest position but trimmed equity for options, closed IVA, and discusses past trades without new forward calls on most names.
10:00
Aug 21
Aug 21
Multiple community members are holding and accumulating SLS, explicitly targeting a $20 price level. Positive retail momentum and accumulation suggest a potential breakout or continuation of a current run. Go long to ride the retail momentum toward the $20 psychological target. This is a purely momentum/hype-driven play with no fundamental news cited in the thread.
LOW
23:38
Aug 19
Aug 19
The author lists speculative biotech catalysts and best ideas by therapeutic area.
The author lists speculative biotech catalysts and best ideas by therapeutic area as research/watchlist content, not explicit current positions or forward calls.
23:36
Aug 19
Aug 19
Upcoming year-end binary data catalysts noted
Highlights upcoming year-end data catalysts for these biotech names, providing estimated upside and downside scenarios.
MED
01:44
Aug 19
Aug 19
Maintains active short position in stock.
Author confirms maintaining an active short position, correcting the phrasing of the question.
MED
12:54
Aug 18
Aug 18
The author agrees with the parent's shady-company characterization but only calls management's.
The author agrees with the parent's shady-company characterization but only calls management's use of bots sketchy, not a directional trade.
LOW
22:14
Aug 17
Aug 17
Author criticizes SLS for posting promotional content and planning an event during its quiet.
Author criticizes SLS for posting promotional content and planning an event during its quiet period, implying governance concerns but no explicit trade position.
LOW
22:10
Aug 17
Aug 17
SLS promotional conduct during quiet period flagged.
Alleges SLS engaged in promotional activity during quiet period and plans an 80th event during quiet period; no directional trade thesis.
MED
13:04
Aug 17
Aug 17
Reports options positioning data for Q2.
Reports options positioning data showing funds holding calls and puts, no directional view.
MED
11:27
Aug 15
Aug 15
The author compiles a thread of user-recommended non-AI tickers as a research watchlist.
The author compiles a thread of user-recommended non-AI tickers as a research watchlist, explicitly noting he cannot guarantee they are all non-AI, so these are indexed as watch rather than trade ideas.
LOW
17:49
Aug 14
Aug 14
Announces expert call on Sellas Life Sciences
Announces an upcoming expert call regarding Sellas Life Sciences with an AML specialist.
LOW
20:04
Aug 13
Aug 13
Author complains their short book is underperforming while longs dominate.
Author complains their short book is underperforming while longs dominate, listing prior short candidates as context rather than fresh trade calls.
10:47
Aug 12
Aug 12
Author lists seven short-selling opportunities with specific bearish catalysts like competition.
Author lists seven short-selling opportunities with specific bearish catalysts like competition and overvaluation, signaling a clear short thesis on each.
22:51
Aug 11
Aug 11
Hosting KOL calls to discuss SELLAS
Author is hosting key opinion leader calls with AML specialists to discuss SELLAS Life Sciences.
LOW
09:17
Aug 03
Aug 03
SLS called a dud in reply commentary
Bearish on SLS: the author says the stock remains a dud and frames the prior decision as portfolio management rather than a positive clinical-data view.
LOW
22:36
Aug 02
Aug 02
SLS short closed, double-digit profit taken
Author closed profitable short position in SLS (double-digit return) to free margin for long-side dip buying; exit was tactical, not thesis-driven.
MED
16:52
Jul 27
Jul 27
Short SLS; trial is statistically powered to land exactly on the significance boundary.
Short SLS; trial is statistically powered to land exactly on the significance boundary with zero margin — any control arm outperformance (likely given responder-enriched enrollment) causes a miss, and the GPS/WT1 peptide vaccine mechanism has failed every prior randomized trial.
HIGH
14:48
Jul 22
Jul 22
Short SLS as the Phase 3 trial is mechanically designed to barely cross significance.
Short SLS as the Phase 3 trial is mechanically designed to barely cross significance, control survival likely exceeds assumptions, and WT1 vaccines have a consistent record of failure in randomized trials.
MED
18:41
Jul 20
Jul 20
Short on prepared bearish report; entry triggered by biotech strength or adverse catalyst.
MED
About SLS Analyst Coverage
Buzzberg tracks SLS (SELLAS Life Sciences Group, Inc. Common Stock) across 9 sources. 7 bullish vs 4 bearish calls from 13 analysts. Sentiment: predominantly bullish (8%). 40 total trade ideas tracked. Past 7 days: 1 bullish, 1 bearish, 4 watch. Latest voices: u/Ateyo94, u/DieOnYourFeat, u/Crackbreaker1.